FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1906721103> ?p ?o ?g. }

• W1906721103 endingPage "65" @default.
• W1906721103 startingPage "59" @default.
• W1906721103 abstract "PURPOSE Osteolytic metastases often give rise to hypercalcemia, fracture, and bone pain, and occur commonly in patients with recurrent breast cancer. We assessed the bisphosphonate, clodronate, which has proven to be a useful treatment for hypercalcemia and may be a potent inhibitor of tumor-induced osteolysis, for its effect on reducing the osseous complications of metastatic breast cancer. PATIENTS AND METHODS We studied 173 patients with bone metastases due to breast cancer in a randomized, double-blind, placebo-controlled trial of oral clodronate 1,600 mg/d (85 patients) compared with an identical placebo (88 patients). RESULTS The patients in each wing were comparable in their clinical, radiologic, and biochemical characteristics at trial entry. In patients who received clodronate, there was a significant reduction compared with placebo in the total number of hypercalcemic episodes (28 v 52; P < .01), in the number of terminal hypercalcemic episodes (seven v 17; P < .05), in the incidence of vertebral fractures (84 v 124 per 100 patient-years; P < .025), and in the rate of vertebral deformity (168 v 252 per 100 patient-years; P < .001). The combined rate of all morbid skeletal events was significantly reduced (218.6 v 304.8 per 100 patient-years; P < .001). Trends were seen in favor of clodronate for nonvertebral fracture rates and radiotherapy requirements for bone pain (particularly spinal pain). No significant survival differences and no significant differences in side effects were observed between the two groups. CONCLUSIONS These findings indicate that oral clodronate has a beneficial effect on the skeletal morbidity associated with breast cancer and should be considered as antiosteolytic therapy in affected patients. It deserves further investigation as an adjuvant therapy in operable breast cancer and in patients with nonosseous recurrence who are at high risk for bone metastases." @default.
• W1906721103 created "2016-06-24" @default.
• W1906721103 creator A5003291621 @default.
• W1906721103 creator A5007727706 @default.
• W1906721103 creator A5024668584 @default.
• W1906721103 creator A5024756058 @default.
• W1906721103 creator A5037004738 @default.
• W1906721103 creator A5045446124 @default.
• W1906721103 date "1993-01-01" @default.
• W1906721103 modified "2023-10-10" @default.
• W1906721103 title "Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer." @default.
• W1906721103 cites W1591022542 @default.
• W1906721103 cites W1968418396 @default.
• W1906721103 cites W1984716307 @default.
• W1906721103 cites W1985489467 @default.
• W1906721103 cites W2001076963 @default.
• W1906721103 cites W2006217337 @default.
• W1906721103 cites W2023853369 @default.
• W1906721103 cites W2034172400 @default.
• W1906721103 cites W2062992747 @default.
• W1906721103 cites W2089404694 @default.
• W1906721103 cites W2123236589 @default.
• W1906721103 cites W2178871496 @default.
• W1906721103 cites W2220106766 @default.
• W1906721103 cites W2227246587 @default.
• W1906721103 cites W2280162642 @default.
• W1906721103 cites W2337075852 @default.
• W1906721103 cites W2399724666 @default.
• W1906721103 cites W2410844975 @default.
• W1906721103 cites W2415785595 @default.
• W1906721103 cites W2469455025 @default.
• W1906721103 cites W584104604 @default.
• W1906721103 doi "https://doi.org/10.1200/jco.1993.11.1.59" @default.
• W1906721103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8418243" @default.
• W1906721103 hasPublicationYear "1993" @default.
• W1906721103 type Work @default.
• W1906721103 sameAs 1906721103 @default.
• W1906721103 citedByCount "538" @default.
• W1906721103 countsByYear W19067211032012 @default.
• W1906721103 countsByYear W19067211032013 @default.
• W1906721103 countsByYear W19067211032014 @default.
• W1906721103 countsByYear W19067211032015 @default.
• W1906721103 countsByYear W19067211032016 @default.
• W1906721103 countsByYear W19067211032017 @default.
• W1906721103 countsByYear W19067211032018 @default.
• W1906721103 countsByYear W19067211032019 @default.
• W1906721103 countsByYear W19067211032020 @default.
• W1906721103 countsByYear W19067211032021 @default.
• W1906721103 countsByYear W19067211032022 @default.
• W1906721103 countsByYear W19067211032023 @default.
• W1906721103 crossrefType "journal-article" @default.
• W1906721103 hasAuthorship W1906721103A5003291621 @default.
• W1906721103 hasAuthorship W1906721103A5007727706 @default.
• W1906721103 hasAuthorship W1906721103A5024668584 @default.
• W1906721103 hasAuthorship W1906721103A5024756058 @default.
• W1906721103 hasAuthorship W1906721103A5037004738 @default.
• W1906721103 hasAuthorship W1906721103A5045446124 @default.
• W1906721103 hasConcept C121608353 @default.
• W1906721103 hasConcept C126322002 @default.
• W1906721103 hasConcept C126894567 @default.
• W1906721103 hasConcept C141071460 @default.
• W1906721103 hasConcept C142724271 @default.
• W1906721103 hasConcept C204787440 @default.
• W1906721103 hasConcept C27081682 @default.
• W1906721103 hasConcept C2775930923 @default.
• W1906721103 hasConcept C2776139714 @default.
• W1906721103 hasConcept C2776541429 @default.
• W1906721103 hasConcept C2777251235 @default.
• W1906721103 hasConcept C2777783956 @default.
• W1906721103 hasConcept C2781282405 @default.
• W1906721103 hasConcept C509974204 @default.
• W1906721103 hasConcept C530470458 @default.
• W1906721103 hasConcept C71924100 @default.
• W1906721103 hasConceptScore W1906721103C121608353 @default.
• W1906721103 hasConceptScore W1906721103C126322002 @default.
• W1906721103 hasConceptScore W1906721103C126894567 @default.
• W1906721103 hasConceptScore W1906721103C141071460 @default.
• W1906721103 hasConceptScore W1906721103C142724271 @default.
• W1906721103 hasConceptScore W1906721103C204787440 @default.
• W1906721103 hasConceptScore W1906721103C27081682 @default.
• W1906721103 hasConceptScore W1906721103C2775930923 @default.
• W1906721103 hasConceptScore W1906721103C2776139714 @default.
• W1906721103 hasConceptScore W1906721103C2776541429 @default.
• W1906721103 hasConceptScore W1906721103C2777251235 @default.
• W1906721103 hasConceptScore W1906721103C2777783956 @default.
• W1906721103 hasConceptScore W1906721103C2781282405 @default.
• W1906721103 hasConceptScore W1906721103C509974204 @default.
• W1906721103 hasConceptScore W1906721103C530470458 @default.
• W1906721103 hasConceptScore W1906721103C71924100 @default.
• W1906721103 hasIssue "1" @default.
• W1906721103 hasLocation W19067211031 @default.
• W1906721103 hasLocation W19067211032 @default.
• W1906721103 hasOpenAccess W1906721103 @default.
• W1906721103 hasPrimaryLocation W19067211031 @default.
• W1906721103 hasRelatedWork W1975355570 @default.
• W1906721103 hasRelatedWork W2014223559 @default.
• W1906721103 hasRelatedWork W2017280060 @default.
• W1906721103 hasRelatedWork W2041686004 @default.

• next